Search Within

Anita Kumar

  1. "Biostatistics Service"
Formats
  1. Meeting Abstract (28)
  2. Journal Article (21)
Groups
  1. Biostatistics Service (49)
  2. Center for Hematologic Malignancies (49)
  3. Department of Medicine (49)
  4. Epidemiology and Biostatistics (49)
  5. Hematologic Malignancies, Division of (49)
  6. Lymphoma (49)

More Groups

People
  1. Andrew Zelenetz (47)
  2. Anas Younes (37)
  3. Matthew Matasar (37)
  4. Maria Palomba (36)
  5. Alison Moskowitz (35)
  6. Paul Hamlin (35)

More People

Years
  1. 2025 (1)
  2. 2024 (2)
  3. 2023 (4)
  4. 2022 (4)
  5. 2021 (6)
  6. 2020 (5)

More Years

Publications
  1. Blood (23)
  2. Hematological Oncology (8)
  3. Blood Cancer Journal (5)
  4. Blood Advances (4)
  5. Haematologica (2)
  6. British Journal of Haematology (1)

More Publications

Publishers
  1. American Society of Hematology (27)
  2. Wiley Blackwell (8)
  3. Nature Publishing Group (5)
  4. Elsevier Inc. (2)
  5. Ferrata Storti Foundation (2)
  6. American Association for Cancer Research (1)

More Publishers

Results (49)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Zanubrutinib, obinutuzumab, and venetoclax for first-line treatment of mantle cell lymphoma with a TP53 mutation
    Journal Article

    Kumar, A.; Soumerai, J.; Abramson, J. S.; Barnes, J. A.; Caron, P.; Chhabra, S.; Chabowska, M.; Dogan, A.; Falchi, L.; Grieve, C.; more...
    Blood (2025)

    Fulltext@MSK | Save
  • Tumor determinants of response to CAR-T therapy in relapsed or refractory mantle cell lymphoma
    Meeting Abstract

    Epstein-Peterson, Z. D.; Ryan, C. E.; Devlin, S. M.; Accav, N. G.; Avigdor, A.; Corona, M.; Danylesko, I.; Dela Cruz, J.; Goy, A.; Jacobson, C. A.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Final response and survival results from a phase II trial of pembrolizumab and entinostat in relapsed/refractory Hodgkin lymphoma
    Meeting Abstract

    Stuver, R.; Vardhana, S. A.; Ganesan, N.; Boardman, A. P.; Caron, P.; Chang, T.; David, K. A.; Epstein-Peterson, Z. D.; Falchi, L.; Ghione, P.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • A phase 2 study of minimal residual disease (MRD)-adapted front line venetoclax and obinutuzumab in fit patients with chronic lymphocytic leukemia (CLL): Effect of obinutuzumab on tumor lysis syndrome (TLS) risk and safety of outpatient venetoclax dose escalation
    Meeting Abstract

    Roeker, L. E.; Zelenetz, A. D.; Park, J. H.; Derkach, A.; Geyer, M. B.; Islam, P.; Falchi, L.; Palomba, M. L.; Kumar, A.; Salles, G.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Real-world outcomes in patients with transformed follicular lymphoma treated with CD19-targeting CAR-T therapy
    Meeting Abstract

    Rivas-Delgado, A.; Luttwak, E.; Drill, E.; Goldstein, I.; Landego, I.; Tomas, A. A.; Parascondola, A.; Saldia, A.; Caron, P.; Dahi, P. B.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • A multicenter phase 2 trial of zanubrutinib, obinutuzumab, and venetoclax (BOVen) in patients with treatment-naïve, TP53-mutant mantle cell lymphoma
    Meeting Abstract

    Kumar, A.; Soumerai, J.; Abramson, J. S.; Barnes, J. A.; Caron, P.; Chabowska, M.; Devlin, M.; Dogan, A.; Falchi, L.; Garcia, R. N.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Long‐term follow-up of multicenter phase II trial of zanubrutinib, obinutuzumab, and venetoclax (BOVen) in previously untreated patients with CLL/SLL
    Meeting Abstract

    Soumerai, J. D.; Dogan, A.; Seshan, V.; Flaherty, K.; Carter, J.; Hochberg, E.; Barnes, J. A.; Abramson, J. S.; Hamilton, A. M.; Noy, A.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Molecular profiling across lymphoma subtypes using MSK-impact next generation sequencing
    Meeting Abstract

    Batlevi, C. L.; Drill, E.; Okwali, M.; Ptashkin, R.; Caron, P. C.; Epstein-Peterson, Z. D.; Falchi, L.; Hamilton, A.; Hamlin, P. A.; Horwitz, S. M.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • A phase 1 trial of copanlisib plus ibrutinib in relapsed/refractory mantle cell lymphoma
    Journal Article

    Qualls, D.; Lam, H. Y.; Whiting, K.; Kumar, A.; Matasar, M.; Owens, C.; Nichols, C.; Espeleta, J. A.; Qiu, A.; Subzwari, S.; more...
    Blood Advances (2022)

    Fulltext@MSK | Save
  • Clinical outcomes with use of radiation therapy and risk of transformation in early-stage follicular lymphoma
    Journal Article

    Sha, F.; Okwali, M.; Alperovich, A.; Caron, P. C.; Falchi, L.; Hamilton, A.; Hamlin, P. A.; Horwitz, S. M.; Joffe, E.; Khan, N.; more...
    Blood Cancer Journal (2022)

    Fulltext@MSK | Save